King W A, Black K L, Ikezaki K, Conklin S, Becker D P
Brain Research Institute, Jonsson Cancer Center, Los Angeles, California.
Acta Neurochir Suppl (Wien). 1990;51:160-2. doi: 10.1007/978-3-7091-9115-6_54.
The efficacy of the potent lipid peroxidation inhibitors U-74006F and U-78517F in the treatment of blood-tumour barrier permeability and tumour associated neurological dysfunction was evaluated. Rats with stereotactically implanted Walker 256 tumours were treated with methylprednisolone (MP), U-74006F, U-78517F, or vehicle. (0.05 N HCl) on days 6 through 10 following implantation. Neurologic function and vascular permeability was assessed on day 10. U-74006F and MP were equally effective at preventing neurologic dysfunction compared to control (p less than 0.01). U-78517F was slightly less effective than U-74006F and MP but was significantly better than vehicle in preventing neurological dysfunction. MP resulted in a significant decrease in tumour vascular permeability (p less than 0.006) while the lipid peroxidation inhibitors had no effect on permeability.
评估了强效脂质过氧化抑制剂U - 74006F和U - 78517F在治疗血瘤屏障通透性和肿瘤相关神经功能障碍方面的疗效。对立体定向植入Walker 256肿瘤的大鼠，在植入后第6至10天用甲基强的松龙（MP）、U - 74006F、U - 78517F或赋形剂（0.05N盐酸）进行治疗。在第10天评估神经功能和血管通透性。与对照组相比，U - 74006F和MP在预防神经功能障碍方面同样有效（p＜0.01）。U - 78517F在预防神经功能障碍方面的效果略低于U - 74006F和MP，但明显优于赋形剂。MP导致肿瘤血管通透性显著降低（p＜0.006），而脂质过氧化抑制剂对通透性无影响。
